Accepted Manuscript

Title: Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies

Authors: Mathew Kelly, Douglas McNeel, Paul Fisch, Miroslav Malkovsky



 PII:
 S0165-2478(17)30437-6

 DOI:
 https://doi.org/10.1016/j.imlet.2017.11.001

 Reference:
 IMLET 6135

 To appear in:
 Immunology Letters

 Received date:
 11-9-2017

 Revised date:
 11 > 2017

 Accepted date:
 1-11-2017

 Sourcepted date:
 5-11-2017

Please cite this article as: Kelly Mathew, McNeel Douglas, Fisch Paul, Malkovsky Miroslav.Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies.*Immunology Letters* https://doi.org/10.1016/j.imlet.2017.11.001

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

IMMUNOLOGICAL CONSIDERATIONS UNDERLYING HEAT SHOCK PROTEIN-MEDIATED CANCER VACCINE STRATEGIES

Mathew Kelly¹, Douglas McNeel^{2,3}, Paul Fisch⁴, Miroslav Malkovsky^{2,5}

¹Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

²University of Wisconsin Carbone Cancer Center, Madison, WI, USA

³Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

⁴Universitätsklinikum Freiburg, Institut für Pathologie, Freiburg, Germany

⁵Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Corresponding author: Miroslav Malkovsky, MD, PhD, FRCPath, Microbial Sciences Building, 1550 Linden Drive, Madison, WI 53706, USA

Highlights

- Active immunotherapy has proven effective for the treatment of some types of prostate cancer.
- Combination therapy involving active immunotheraputic strategies show promising results in clinical trials.
- Heat shock proteins (HSPs) may enhace the immunogenicity of active immunotherapies.
- Overexpression of intracellular and extracellular HSPs may most efficiently exploit their full immunostimulatory potential.

Abstract

The success of active immunotherapies in the prevention of many infectious diseases over the

course of over 200 years has lead scientists to wonder if the same principles could be applied to

cancer. Antigen-specific active immunotherapies for the treatment of cancer have been

researched for over two decades, however, the overwhelming majority of these studies have

Download English Version:

https://daneshyari.com/en/article/8738382

Download Persian Version:

https://daneshyari.com/article/8738382

Daneshyari.com